Individual RASSF1 CpG site analysis allows separation of epigenetic silencing at RASSF1‐1α from RASSF1‐2γ and therefore study of the differential contribution of the tumor suppressor RASSF1A from the oncogenic RASSF1C isoform to disease progression (Fig 6A, Appendix Fig S3A). This evidence concerns the gene RASSF1 and neoplasm.